• 21 May 25
 

J.P. Morgan SE - Stabilisation Notice


 
RNS Number : 5799J
J.P. Morgan SE
21 May 2025
 

21st May 2025

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Teva Pharmaceutical Finance Netherlands IV BV / Teva Pharmaceutical Finance Netherlands III BV

Post-stabilisation Period Announcement

Further to the pre-stabilisation period announcement dated 20th May 2025, J.P. Morgan S E, (contact: Natalie Netter Day +442071342468) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014) or the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

Issuer:

Teva Pharmaceutical Finance Netherlands IV BV / Teva Pharmaceutical Finance Netherlands III BV 

Guarantor (if any):

N/A

Aggregate nominal amount:

USD 700mm 5.5yr

USD 500mm 7.5yr

Description:

EUR 3yr FXD Senior Unsecured Notes

EUR 7yr FXD Senior Unsecured Notes

SEC registered

Listing: New York Stock Exchange

Stabilisation Manager(s):

J.P. Morgan S.E (Stabilisation coordinator)

BNP Paribas (Stabilisation manager)

Citibank (Stabilisation manager)

Societe Generale (Stabilisation manager)

Offer price:

5.5yr - 99.418%

7.5yr - 99.256%

 

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STAFIFEDERILFIE

Research Tree RNS Article

To continue viewing this RNS article, please advise if you are one of the following:

Return to News Summary